In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation

Journal of Clinical Investigation

Volumn 117, Issue 12, 2007, Pages 3868-3878

  Seshasayee, Dhaya ^a   Lee, Wyne P ^a   Zhou, Meijuan ^a   Shu, Jean ^a   Suto, Eric ^a   Zhang, Juan ^a   Diehl, Laurie ^a   Austin, Cary D ^a   Meng, Y Gloria ^a   Tan, Martha ^a   Bullens, Sherron L ^a   Seeber, Stefan ^b   Fuentes, Maria E ^c   Labrijn, Aran F ^d   Graus, Yvo M F ^d   Miller, Lisa A ^e   Schelegle, Edward S ^e   Hyde, Dallas M ^e   Wu, Lawren C ^a   Hymowitz, Sarah G ^a,e   Martin, Flavius ^a   more..

^a GENENTECH INC   (United States)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c ROCHE BIOSCIENCE   (United States)

^d GENMAB   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA OX40 LIGAND MONOCLONAL ANTIBODY; CD134 ANTIGEN; CD40 ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 7; MONOCLONAL ANTIBODY; THYMIC STROMAL LYMPHOPOIETIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN FUNCTION; ARTICLE; ASTHMA; ATOPIC DERMATITIS; ATOPY; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO STUDY; LYMPHOPOIESIS; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN INFLAMMATION; TH2 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; CRICETINAE; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; INFLAMMATION; LUNG; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; OX40 LIGAND; RECEPTORS, OX40; SKIN; TH2 CELLS; TUMOR NECROSIS FACTORS;

EID: 36849060458     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33559     Document Type: Article

References (35)

1. Cohn, L., Elias, J.A., and Chupp, G.L. 2004. Asthma: mechanisms of disease persistence and progression. Annu. Rev. Immunol. 22:789-815.
2. Watts, T.H. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23:23-68.
3. Salek-Ardakani, S., and Croft, M. 2006. Regulation of CD4 T cell memory by OX40 (CD134). Vaccine. 24:872-883.
4. So, T., Lee, S.W., and Croft, M. 2006. Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity. Int. J. Hematol. 83:1-11.
5. Kotani, A., et al. 2007. Involvement of OX40 ligand+ mast cells in chronic GVHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 39:373-375.
6. Sugamura, K., Ishii, N., and Weinberg, A.D. 2004. Therapeutic targeting of the effector T-cell costimulatory molecule OX40. Nat. Rev. Immunol. 4:420-431.
7. Chen, A.I., et al. 1999. Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity. 11:689-698.
8. Flynn, S., Toellner, K.M., Raykundalia, C., Goodall, M., and Lane, P. 1998. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J. Exp. Med. 188:297-304.
9. Gramaglia, I., Weinberg, A.D., Lemon, M., and Croft, M. 1998. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161:6510-6517.
10. Salek-Ardakani, S., et al. 2003. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J. Exp. Med. 198:315-324.
11. Hoshino, A., et al. 2003. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur. J. Immunol. 33:861-869.
12. Kopf, M., et al. 1999. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity. 11:699-708.
13. Ishii, N., et al. 2003. OX40 (CD134) and OX40 ligand interaction plays an adjuvant role during in vivo Th2 responses. Eur. J. Immunol. 33:2372-2381.
14. Ndhlovu, L.C., Ishii, N., Murata, K., Sato, T., and Sugamura, K. 2001. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J. Immunol. 167:2991-2999.
15. Ito, T., et al. 2005. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202:1213-1223.
16. Soumelis, V., et al. 2002. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 3:673-680.
17. Ying, S., et al. 2005. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J. Immunol. 174:8183-8190.
18. Zhou, B., et al. 2005. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat. Immunol. 6:1047-1053.
19. Yoo, J., et al. 2005. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J. Exp. Med. 202:541-549.
20. Liu, Y.J., et al. 2007. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu. Rev. Immunol. 25:193-219.
21. Liu, Y.J. 2006. Thymic stromal lymphopoietin: master switch for allergic inflammation. J. Exp. Med. 203:269-273.
22. Shields, R.L., et al. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276:6591-6604.
23. Epstein, M.M. 2004. Do mouse models of allergic asthma mimic clinical disease? Int. Arch. Allergy Immunol. 133:84-100.
24. Wang, Y.H., et al. 2006. Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity. 24:827-838.
25. Kim, C.K., et al. 2003. Bronchoalveolar lavage cytokine profiles in acute asthma and acute bronchiolitis. J. Allergy Clin. Immunol. 112:64-71.
26. Ito, T., et al. 2006. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 103:13138-13143.
27. Higgins, L.M., et al. 1999. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J. Immunol. 162:486-493.
28. Yoshioka, T., et al. 2000. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur. J. Immunol. 30:2815-2823.
29. Allakhverdi, Z., et al. 2007. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J. Exp. Med. 204:253-258.
30. Astrakhan, A., et al. 2007. Local increase in thymic stromal lymphopoietin induces systemic alterations in B cell development. Nat. Immunol. 8:522-531.
31. Rochman, I., Watanabe, N., Arima, K., Liu, Y.J., and Leonard, W.J. 2007. Cutting Edge: Direct action of thymic stromal lymphopoietin on activated human CD4+ T cells. J. Immunol. 178:6720-6724.
32. Vosshenrich, C.A., Cumano, A., Muller, W., Di Santo, J.P., and Vieira, P. 2004. Pre-B cell receptor expression is necessary for thymic stromal lymphopoietin responsiveness in the bone marrow but not in the liver environment. Proc. Natl. Acad. Sci. U. S. A. 101:11070-11075.
33. Nakae, S., et al. 2006. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 176:2238-2248.
34. Fishwild, D.M., et al. 1996. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14:845-851.
35. Schelegle, E.S., et al. 2001. Allergic asthma induced in rhesus monkeys by house dust mite (Dermatophagoides farinae). Am. J. Pathol. 158:333-341.